(Q41241880)

28 September 2017

title

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients (English)

1 reference

28 September 2017

M Hecht

1

1 reference

28 September 2017

L Zimmer

2

1 reference

28 September 2017

C Loquai

3

1 reference

28 September 2017

C Weishaupt

4

1 reference

28 September 2017

R Gutzmer

5

1 reference

28 September 2017

B Schuster

6

1 reference

28 September 2017

S Gleisner

7

1 reference

28 September 2017

B Schulze

8

1 reference

28 September 2017

S M Goldinger

9

1 reference

28 September 2017

C Berking

10

1 reference

28 September 2017

A Forschner

11

1 reference

28 September 2017

P Clemens

12

1 reference

28 September 2017

G Grabenbauer

13

1 reference

28 September 2017

T Müller-Brenne

14

1 reference

28 September 2017

J Bauch

15

1 reference

28 September 2017

H T Eich

16

1 reference

28 September 2017

S Grabbe

17

1 reference

28 September 2017

D Schadendorf

18

1 reference

28 September 2017

G Schuler

19

1 reference

28 September 2017

P Keikavoussi

20

1 reference

28 September 2017

S Semrau

21

1 reference

28 September 2017

R Fietkau

22

1 reference

28 September 2017

L V Distel

23

1 reference

28 September 2017

L Heinzerling

24

1 reference

28 September 2017

publication date

11 March 2015

1 reference

28 September 2017

1 reference

28 September 2017

volume

26

1 reference

28 September 2017

issue

6

1 reference

28 September 2017

page(s)

1238-1244

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Melanoma brain metastasis: overview of current management and emerging targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Vemurafenib and radiation therapy in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Cutaneous effects of BRAF inhibitor therapy: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Paradoxical oncogenesis: are all BRAF inhibitors equal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV139

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV139

1 reference

28 September 2017

1 reference